Spray-Dried TRPC5 Inhibitor Dispersion for Stable Solid Dosage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective methods to treat or reduce the risk of developing kidney diseases such as proteinuria, as well as other conditions like anxiety and depression, by targeting the TRPC5 channels, which are involved in the pathophysiology of these disorders.
Innovation Solution
A spray-dried dispersion formulation of the TRPC5 inhibitor 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, combined with a polymer like hypromellose acetate succinate, is developed for solid dosage forms to treat kidney diseases and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target CCR5, then the ability to cross cell membranes and block CCR5 is improved, but the development of resistance by HIV and lack of cellular selectivity worsens
Solution Approach 1:
The patent changes the molecular parameter from small molecule to large molecule (protein/peptide), fundamentally altering the interaction mechanism with CCR5 to achieve both effective blocking and cellular selectivity while reducing resistance development
Solution Approach 2:
The invention uses chimeric proteins combining scFv (antibody fragment) with CCR5 transmembrane domains, creating a composite structure that integrates antigen recognition with membrane insertion capabilities to achieve both CCR5 blocking and cellular targeting
2Reliability
If CCR5 antagonists are administered, then HIV infection is blocked, but gastrointestinal side effects worsen
Solution Approach 1:
The patent introduces cell-type specific targeting through the scFv component that directs the chimeric protein to specific cells expressing the target antigen, thereby limiting CCR5 blockade to infected cells and sparing healthy gastrointestinal cells from side effects
Solution Approach 2:
The scFv component acts as an intermediary that provides antigen-specific recognition and targeting, mediating between the administered chimeric protein and the infected cells, enabling selective action at the site of infection while protecting healthy tissues
3Productivity
If T-cell lines are used to produce CCR5 antibodies, then antibody production is achieved, but cross-reactivity with other chemokine receptors worsens
Solution Approach 1:
The patent uses different cell lines for different production stages: HEK293 cells for initial scFv production and CHO cells for final chimeric protein production, with each cell type optimized for specific requirements to maintain specificity while ensuring productivity
Solution Approach 2:
The invention changes the production system from simple antibody secretion to complex chimeric protein expression requiring specialized cell lines with appropriate transcriptional and translational machinery to handle the sophisticated protein structure and maintain specificity
4Reliability
If lipophilic CCR5 antagonists are used, then CCR5 binding is achieved, but accumulation in fatty tissues and gastrointestinal side effects worsen
Solution Approach 1:
The patent fundamentally changes the drug parameter from lipophilic small molecule to hydrophilic large molecule (chimeric protein), altering distribution patterns to prevent fatty tissue accumulation while maintaining CCR5 binding through the transmembrane domain interaction
Solution Approach 2:
The chimeric protein combines hydrophilic scFv with transmembrane CCR5 domains, creating a composite structure that binds CCR5 through hydrophobic interactions while the overall protein remains hydrophilic and does not accumulate in fatty tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively treats kidney diseases and reduces the risk of developing conditions like anxiety and depression with minimal side effects, providing a prophylactic and therapeutic approach.
Implementation Method 1
spray-dried formulation
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Disclosed are spray-dried formulations of 4-chloro-5-(4-(4-fluoro-2- (trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, methods and compositions for making the same, and solid dosage forms comprising the same. The dosage forms described herein are useful in methods of treating kidney diseases or neuropathies associated with diseases or conditions, and in methods of treating pain, anxiety, or depression.